Limits...
Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus.

Sun L, Kwok E, Gopaluni B, Vahidi O - Open Biomed Eng J (2011)

Bottom Line: However, its effects on patients are derived usually from clinical experiments.The combination treatment of insulin infusion plus oral metformin is shown to be superior than the monotherapy with oral metformin only.These results are consistent with the clinical understanding of the use of metformin.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemical and Biological Engineering, University of British Columbia, 2360 East Mall Vancouver, BC, Canada, V6T 1Z3.

ABSTRACT
Metformin is an antihyperglycemic agent commonly used for the treatment of Type II diabetes mellitus. However, its effects on patients are derived usually from clinical experiments. In this study, a dynamic model of Type II diabetes mellitus with the treatment of metformin is proposed. The Type II diabetic model is a modification of an existing compartmental diabetic model. The dynamic simulation of the metformin effect for a Type II diabetic patient is based on the pharmacokinetic and pharmacodynamic relationship with a human body. The corresponding model parameters are estimated by optimization using clinical data from published reports. Then, the effect of metformin in both intravenous and oral administration on a Type II diabetes mellitus model are compared. The combination treatment of insulin infusion plus oral metformin is shown to be superior than the monotherapy with oral metformin only. These results are consistent with the clinical understanding of the use of metformin. For further work, the model can be analyzed for evaluating the treatment of diabetes mellitus with different pharmacological agents.

No MeSH data available.


Related in: MedlinePlus

Plasma glucose concentration of type II diabetic patients who received 500mg of metformin by intravenous and oral administrations.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3102322&req=5

Figure 4: Plasma glucose concentration of type II diabetic patients who received 500mg of metformin by intravenous and oral administrations.

Mentions: The simulation results of glucose concentrations following the intravenous and oral administrations are shown in Fig. (4). Since the clinical data are measured from healthy human [13, 14], comparing them with the simulated diabetic data is not appropriate. Instead, the dynamic simulation of a Type II diabetic patient with no metformin effect was performed to compare with the effect of metformin for Type II diabetic patients.


Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus.

Sun L, Kwok E, Gopaluni B, Vahidi O - Open Biomed Eng J (2011)

Plasma glucose concentration of type II diabetic patients who received 500mg of metformin by intravenous and oral administrations.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3102322&req=5

Figure 4: Plasma glucose concentration of type II diabetic patients who received 500mg of metformin by intravenous and oral administrations.
Mentions: The simulation results of glucose concentrations following the intravenous and oral administrations are shown in Fig. (4). Since the clinical data are measured from healthy human [13, 14], comparing them with the simulated diabetic data is not appropriate. Instead, the dynamic simulation of a Type II diabetic patient with no metformin effect was performed to compare with the effect of metformin for Type II diabetic patients.

Bottom Line: However, its effects on patients are derived usually from clinical experiments.The combination treatment of insulin infusion plus oral metformin is shown to be superior than the monotherapy with oral metformin only.These results are consistent with the clinical understanding of the use of metformin.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemical and Biological Engineering, University of British Columbia, 2360 East Mall Vancouver, BC, Canada, V6T 1Z3.

ABSTRACT
Metformin is an antihyperglycemic agent commonly used for the treatment of Type II diabetes mellitus. However, its effects on patients are derived usually from clinical experiments. In this study, a dynamic model of Type II diabetes mellitus with the treatment of metformin is proposed. The Type II diabetic model is a modification of an existing compartmental diabetic model. The dynamic simulation of the metformin effect for a Type II diabetic patient is based on the pharmacokinetic and pharmacodynamic relationship with a human body. The corresponding model parameters are estimated by optimization using clinical data from published reports. Then, the effect of metformin in both intravenous and oral administration on a Type II diabetes mellitus model are compared. The combination treatment of insulin infusion plus oral metformin is shown to be superior than the monotherapy with oral metformin only. These results are consistent with the clinical understanding of the use of metformin. For further work, the model can be analyzed for evaluating the treatment of diabetes mellitus with different pharmacological agents.

No MeSH data available.


Related in: MedlinePlus